Molecular and Cellular Biology of Thrombopoietin
血小板生成素的分子和细胞生物学
基本信息
- 批准号:7624000
- 负责人:
- 金额:$ 23.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-06-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingBenignBindingBlood Platelet DisordersBlood PlateletsCell LineCell SurvivalCellsClassificationConditionCongenital DisordersCytokine SignalingDevelopmentDown-RegulationEndocytosisEndosomesErythropoiesisErythropoietinErythropoietin ReceptorEtiologyEventFinancial compensationFocal Adhesion Kinase 1Hematologic NeoplasmsHemorrhagic ThrombocythemiaHomologous GeneLinkLysosomesMeasuresMegakaryocytesMegakaryocytopoiesesModelingMolecular and Cellular BiologyMusMutateMutationMyeloproliferative diseasePathway interactionsPatientsPeptidesPersonal SatisfactionPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPhosphotyrosinePhysiologyPlatelet Count measurementPolycythemia VeraPrimary MyelofibrosisProcessProductionProteinsRecyclingRegulationResidual stateRoleSignal PathwaySignal TransductionSurfaceThrombocytopeniaThrombopoiesisThrombopoietinTyrosineUbiquitinationcell growth regulationcytokineglycosylationhuman MPL proteinloss of functionmimeticsneoplasticpreventprotein protein interactionreceptorreceptor sensitivityresponsesrc Homology Region 2 Domainsrc-Family Kinasestensinthrombocytosistooltraffickingubiquitin ligase
项目摘要
Thrombopoietin (TPO) is the primary regulator of thrombopoiesis. Through its
interaction with the c-Mpl receptor, TPO initiates a signaling cascade by triggering the
phosphorylation and activation of Jak2. Although this is well established, it remains
unclear as to how TPO signaling is modulated, which has important consequences for
the regulation of cell growth and differentiation. Dysregulation of TPO signaling, as
exemplified by mutations conferring constitutive activity to Jak2 or c-Mpl, is known to
underlie the development of congenital and acquired myeloproliferative disorders
(MPDs), including polycythemia vera (PV), essential thrombocythemia (ET) and
idiopathic myelofibrosis (IMF). In addition, TPO-mimetics are emerging as important
tools for the treatment of patients with thrombocytopenia of both benign and neoplastic
etiologies. In this competitive renewal we propose to study the regulation of TPO
signaling, including: 1) c-Mpl receptor trafficking and internalization in response to TPO,
2) negative regulation of TPO signaling, including the potential effects of receptor
ubiquitination, Src family kinases and phosphatase and tensin homologue (PTEN) for
megakaryopoiesis, and 3) functional similarities and differences between TPO and
erythropoietin (EPO) signaling.
血小板生成素(TPO)是血小板生成的主要调节因子。通过其
TPO与c-Mpl受体相互作用,通过触发细胞内的信号传导,
磷酸化和激活Jak 2。虽然这是既定的,但它仍然是
不清楚TPO信号是如何调节的,这对
细胞生长和分化的调节。TPO信号转导失调,如
例如赋予Jak 2或c-Mpl组成型活性的突变,已知
先天性和后天性骨髓增生性疾病的基础
(MPD),包括真性红细胞增多症(PV)、原发性血小板增多症(ET)和
特发性骨髓纤维化(IMF)。此外,TPO模拟物正在成为重要的
用于治疗良性和肿瘤性血小板减少症患者的工具
病因学在这次竞争性续约中,我们建议研究TPO的监管
信号传导,包括:1)响应TPO的c-Mpl受体运输和内化,
2)TPO信号的负调节,包括受体的潜在作用
泛素化,Src家族激酶和磷酸酶和张力蛋白同源物(PTEN),
巨核细胞生成,以及3)TPO和
促红细胞生成素(EPO)信号传导。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AMY E GEDDIS其他文献
AMY E GEDDIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AMY E GEDDIS', 18)}}的其他基金
ANTI-IDIOTYPE MONOCLONAL ANTIBODY AS A TUMOR VACCINE FOR NEUROBLASTOMA
抗独特型单克隆抗体作为神经母细胞瘤的肿瘤疫苗
- 批准号:
7205566 - 财政年份:2003
- 资助金额:
$ 23.56万 - 项目类别:
Anti-Idiotype MAB as a Tumor Vaccine for Neuroblastoma
抗独特型 MAB 作为神经母细胞瘤肿瘤疫苗
- 批准号:
7045384 - 财政年份:2003
- 资助金额:
$ 23.56万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6597567 - 财政年份:2001
- 资助金额:
$ 23.56万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6856480 - 财政年份:2001
- 资助金额:
$ 23.56万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6683245 - 财政年份:2001
- 资助金额:
$ 23.56万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6226398 - 财政年份:2001
- 资助金额:
$ 23.56万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6721328 - 财政年份:2001
- 资助金额:
$ 23.56万 - 项目类别:
Molecular and Cellular Biology of Thrombopoietin
血小板生成素的分子和细胞生物学
- 批准号:
8218783 - 财政年份:1995
- 资助金额:
$ 23.56万 - 项目类别:
Molecular and Cellular Biology of Thrombopoietin
血小板生成素的分子和细胞生物学
- 批准号:
8496504 - 财政年份:1995
- 资助金额:
$ 23.56万 - 项目类别:
Molecular and Cellular Biology of Thrombopoietin
血小板生成素的分子和细胞生物学
- 批准号:
7652101 - 财政年份:1995
- 资助金额:
$ 23.56万 - 项目类别:
相似海外基金
Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
- 批准号:
23K08495 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
- 批准号:
22KJ2498 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
- 批准号:
10726042 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
- 批准号:
23H03765 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
- 批准号:
23K08075 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
- 批准号:
10720034 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
- 批准号:
2306943 - 财政年份:2023
- 资助金额:
$ 23.56万 - 项目类别:
Standard Grant
Identifying the role of the gut microbiome in the etiology of benign breast disease
确定肠道微生物组在良性乳腺疾病病因学中的作用
- 批准号:
10359959 - 财政年份:2022
- 资助金额:
$ 23.56万 - 项目类别:














{{item.name}}会员




